CDK2

Class

novel selective CDK2 inhibitor

Pathway

inhibits CDK2, a cell-cycle kinase that CCNE1-amplified tumors and CDK4/6-inhibitor-resistant tumors depend on for cell-cycle progression independent of upstream hormone/CDK4/6 signaling

CDK2 (cyclin-dependent kinase 2) is an enzyme that partners with regulatory proteins called cyclins to drive cells through the cell cycle, particularly the transition from growth phase (G1) into DNA synthesis (S phase). In healthy cells, this step is normally gated by CDK4/6 acting on the retinoblastoma protein, with CDK2 acting downstream once cyclin E accumulates. In many cancers, amplification of the gene encoding cyclin E1 (CCNE1) or other adaptations allow CDK2 to become persistently active independent of the usual upstream controls, including in tumors that have become resistant to CDK4/6-inhibiting drugs. Because these tumors no longer depend on the CDK4/6 checkpoint, blocking CDK2 offers a way to re-impose cell-cycle control through a different node in the same pathway. Selective CDK2 inhibitors are designed to interrupt this proliferative signal specifically, distinguishing themselves from older, broader cyclin-dependent kinase inhibitors that also block enzymes needed for normal cell division and gene transcription, which tend to cause more widespread toxicity. This mechanism is relevant across cancers marked by cyclin E excess or acquired resistance to hormone-pathway-linked CDK4/6 therapy, where reintroducing cell-cycle arrest can slow tumor growth.